Nilotinib
Active ingredient: Nilotinib
In short: Nilotinib Capsules is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna ® (nilotinib) capsules.
What is Nilotinib used for?
Nilotinib Capsules is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna
®
(nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Nilotinib Capsules is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib.
Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna
®
(nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
⚠ Boxed warning (FDA's strongest warning)
Nilotinib prolongs the QT interval. Prior to Nilotinib Capsules administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies . Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments .
Sudden deaths have been reported in patients receiving nilotinib . Do not administer Nilotinib Capsules to patients with hypokalemia, hypomagnesemia, or long QT syndrome .
Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors .
Avoid food 2 hours before and 1 hour after taking the dose .
Nilotinib dosage
Dosage in Adult Patients with Newly Diagnosed Ph+ CML-CP
The recommended dosage of Nilotinib Capsules is 300 mg orally twice daily.
Dosage in Adult Patients with Resistant or Intolerant Ph+ CML-CP and CML-AP
The recommended dosage of Nilotinib Capsules is 400 mg orally twice daily.
Additional Administration Instructions
Dose Nilotinib Capsules twice daily at approximately 12-hour intervals on an empty stomach. No food should be consumed for at least 2 hours before the dose is taken and for at least 1 hour after the dose is taken. Advise patients to swallow the capsules whole with water and not open the capsules . If a dose of Nilotinib Capsules is missed, the patient should take the next scheduled dose at its regular time. The patient should not take two doses at the same time.
Optional Concomitant Therapy
Nilotinib Capsules may be given in combination with hematopoietic growth factors, such as erythropoietin or G-CSF if clinically indicated. Nilotinib Capsules may be given with hydroxyurea or anagrelide if clinically indicated.
Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna
®
(nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Patient Selection
Eligibility for Discontinuation of Treatment
Ph+ CML-CP patients with typical BCR-ABL transcripts, who have been taking Nilotinib Capsules for a minimum of 3 years and have achieved a sustained molecular response (MR4.5, corresponding to = BCR-ABL/ABL ≤ 0.0032% IS), may be eligible for treatment discontinuation . Information on FDA authorized tests for the detection and quantitation of BCR-ABL transcripts to determine eligibility for treatment discontinuation is available at http://www.fda.gov/CompanionDiagnostics.
Patients with typical BCR-ABL transcripts (e13a2/b2a2 or e14a2/b3a2), who achieve the sustained MR4.5 criteria, are eligible for discontinuation of Nilotinib Capsules. Patients must continue to be monitored for possible loss of molecular remission after treatment discontinuation. Use the same FDA-authorized test to consistently monitor molecular response levels while on and off treatment. …
How to take Nilotinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Taking Nilotinib Capsules
Advise patients to take Nilotinib Capsules doses twice daily approximately 12 hours apart. Advise patients to swallow the capsules whole with water and not open the capsules.
Advise patients to take Nilotinib Capsules on an empty stomach. No food should be consumed for at least 2 hours before the dose is taken and for at least 1 hour after the dose is taken. Patients should not consume grapefruit products and other foods that are known to inhibit CYP3A4 at any time during Nilotinib Capsules treatment .
If the patient misses a dose of Nilotinib Capsules, the patient should take the next scheduled dose at its regular time. The patient should not take two doses at the same time.
Compliance
Advise patients of the following:
Continue taking Nilotinib Capsules every day for as long as their doctor tells them.
This is a long-term treatment.
Do not change dose or stop taking Nilotinib Capsules without first consulting their doctor.
Myelosuppression
Advise patients that treatment with Nilotinib Capsules can cause serious thrombocytopenia, neutropenia, and anemia. …
Warnings & precautions
Do not take this medicine if: Nilotinib Capsules is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome .
Treatment with Nilotinib Capsules can cause Grade 3/4 thrombocytopenia, neutropenia, and anemia. Perform CBCs every 2 weeks for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Nilotinib Capsules temporarily or dose reduction .
Nilotinib has been shown to prolong cardiac ventricular repolarization as measured by the QT interval on the surface electrocardiogram (ECG) in a concentration-dependent manner . Prolongation of the QT interval can result in a type of ventricular tachycardia called torsade de pointes, which may result in syncope, seizure, and/or death. Electrocardiograms should be performed at baseline, 7 days after initiation of Nilotinib Capsules, and periodically as clinically indicated and following dose adjustments .
Nilotinib Capsules should not be used in patients who have hypokalemia, hypomagnesemia, or long QT syndrome. Before initiating Nilotinib Capsules and periodically, test electrolyte, calcium, and magnesium blood levels. Hypokalemia or hypomagnesemia must be corrected prior to initiating Nilotinib Capsules and these electrolytes should be monitored periodically during therapy .
Significant prolongation of the QT interval may occur when Nilotinib Capsules is inappropriately taken with food and/or strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT. Therefore, avoid coadministration with food and concomitant Nilotinib Capsules use with strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT should be avoided . The presence of hypokalemia and hypomagnesemia may further prolong the QT interval . …
Nilotinib side effects
The following clinically significant adverse reactions can occur with Nilotinib Capsules and are discussed in greater detail in other sections of labeling:
• Myelosuppression
• QT Prolongation
• Sudden Deaths
• Cardiac and Arterial Vascular Occlusive Events
• Pancreatitis and Elevated Serum Lipase
• Hepatotoxicity
• Electrolyte Abnormalities
• Hemorrhage
• Fluid Retention
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In Adult Patients With Newly Diagnosed Ph+ CML-CP
The data below reflect exposure to nilotinib from a randomized trial in patients with newly diagnosed Ph+ CML in chronic phase treated at the recommended dose of 300 mg twice daily (n = 279). The median time on treatment in the nilotinib 300 mg twice daily group was 61 months (range, 0.1 to 71 months). The median actual dose intensity was 593 mg/day in the nilotinib 300 mg twice daily group.
The most common (greater than 10%) non-hematologic adverse drug reactions were rash, pruritus, headache, nausea, fatigue, alopecia, myalgia, and upper abdominal pain. Constipation, diarrhea, dry skin, muscle spasms, arthralgia, abdominal pain, peripheral edema, vomiting, and asthenia were observed less commonly (less than or equal to 10% and greater than 5%). …
Drug interactions
Strong CYP3A Inhibitors
Avoid concomitant use of strong CYP3A inhibitors with Nilotinib Capsules. If concomitant use cannot be avoided, reduce Nilotinib Capsules dose .
Nilotinib is a CYP3A substrate . Concomitant use with a strong CYP3A inhibitor increases nilotinib exposure , which may increase the risk of Nilotinib Capsules adverse reactions.
Strong CYP3A Inducers
Avoid concomitant use of strong CYP3A inducers with Nilotinib Capsules.
Nilotinib is a CYP3A substrate . Concomitant use with a strong CYP3A inducer decreases nilotinib exposure , which may reduce Nilotinib Capsules efficacy.
Proton Pump Inhibitors
Avoid concomitant use of proton pump inhibitors (PPI) with Nilotinib Capsules. As an alternative to PPIs, use H2 blockers approximately 10 hours before or approximately 2 hours after the dose of Nilotinib Capsules, or use antacids approximately 2 hours before or approximately 2 hours after the dose of Nilotinib Capsules.
Nilotinib displays pH-dependent aqueous solubility . Concomitant use with a PPI decreases nilotinib concentrations , which may reduce Nilotinib Capsules efficacy. …
About this medicine
Nilotinib Capsules contains nilotinib d-tartrate, which belongs to a pharmacologic class of drugs known as kinase inhibitors.
Nilotinib d-tartrate is a white to yellow powder with the molecular formula and weight, respectively, of C32H28F3N7O7 and 679.61 g/mol (corresponding molecular formula and weight of nilotinib base, anhydrous are C28H22F3N7O and 529 g/mol, respectively). The solubility of nilotinib d-tartrate in aqueous solutions decreases with increasing pH. The pKa1 of nilotinib d-tartrate was determined to be 4.0.
The chemical name of nilotinib d-tartrate is 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide D-Tartrate. Its structure is shown below:
Nilotinib Capsules, for oral use, contain 50 mg, 150 mg, or 200 mg nilotinib, anhydrous (equivalent to 64.172 mg, 192.517 mg, and 256.689 mg nilotinib d-tartrate, respectively). The inactive ingredients of Nilotinib Capsules are colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium aluminometasilicate, magnesium stearate, and polysorbate 80. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e27c3e09-bc4f-4f01-be05-1c43ac72285d. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate